Venu Bathini, MD
Hematology & Oncology · Framingham, MANPI 1578658563
Payments from drug & device makers
Across 137 payments — averaging $847.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$53K
- Halozyme Inc$42K
- EMD Serono, Inc.$16K
- US Oncology Corporate, Inc.$2K
- Incyte Corporation$336
- Bristol Myers Squibb$242
- plus $2K from 35 others
Across 1 payment — averaging $3752.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$4K
What the payments were for
- Travel & lodging$98424%
- Food & beverage$2,80769%
- Education$2787%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 19 | $53,273 |
| Halozyme Inc | 12 | $42,247 |
| EMD Serono, Inc. | 5 | $16,121 |
| US Oncology Corporate, Inc. | 6 | $1,637 |
| Incyte Corporation | 18 | $336 |
| Bristol Myers Squibb | 8 | $242 |
| AstraZeneca | 6 | $221 |
| Pfizer | 8 | $216 |
| Dendreon Pharmaceuticals LLC | 2 | $148 |
| Exelixis Inc. | 2 | $131 |
| Progenics Pharmaceuticals, Inc. | 1 | $125 |
| Johnson & Johnson(2 entities) | 4 | $108 |
| Novartis | 3 | $95 |
| Merck | 3 | $89 |
| Sobi, Inc | 2 | $87 |
| Eisai Inc. | 3 | $80 |
| Eli Lilly | 1 | $79 |
| Array Biopharma Inc | 3 | $75 |
| GSK | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 2 | $59 |
| Daiichi Sankyo Inc. | 2 | $53 |
| Tempus AI, Inc | 2 | $51 |
| Gilead(2 entities) | 2 | $49 |
| Foundation Medicine, Inc. | 1 | $43 |
| Agios Pharmaceuticals, Inc. | 1 | $39 |
| Bayer | 2 | $37 |
| Legend Biotech USA Inc. | 2 | $36 |
| Beigene USA, Inc. | 1 | $34 |
| Genentech USA, Inc. | 1 | $28 |
| Fresenius Kabi USA, LLC | 1 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $24 |
| Acrotech Biopharma Inc. | 1 | $24 |
| ADC Therapeutics America, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| AbbVie | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Amgen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,062 in reported general payments places this provider in the 65th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 12 | $197,578 |
| XtandiEnzalutamide | 11 | $155,795 |
| EliquisApixaban | 83 | $113,527 |
| XareltoRivaroxaban | 24 | $26,506 |
| Hydroxyurea | 53 | $1,872 |
| ValacyclovirValacyclovir Hcl | 16 | $1,631 |
| Potassium Chloride | 12 | $1,262 |
| Letrozole | 20 | $830 |
| Dexamethasone | 34 | $397 |
| Ondansetron OdtOndansetron | 33 | $396 |
| Pantoprazole Sodium | 22 | $379 |
| Omeprazole | 12 | $172 |
| Oxycodone Hcl | 24 | $154 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $149 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $242 | $197,57812 claims |
| Astellas Pharma US IncXtandi | $18 | $155,79511 claims |
| PfizerEliquis | $216 | $113,52783 claims |
| Johnson & JohnsonXarelto | $108 | $26,50624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 374 hematology & oncology providers in Massachusetts.
Other hematology & oncology in Framingham
- Matthew DavidsBoston$58.6M
- Nadine TungBoston$32.4M
- Jorge CastilloBoston$31.2M
- Daniel DeangeloBoston$28.5M
- Sara TolaneyBoston$20.3M
- Austin KimWorcester$19.3M
- Paul RichardsonBoston$17.2M
- Amir FathiBoston$14.8M
- Jacqueline GarciaBoston$13.6M
- Jacob SandsBurlington$13.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.